Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-059329
Filing Date
2021-11-15
Accepted
2021-11-15 16:04:56
Documents
47
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0921_tffpharma.htm   iXBRL 10-Q 446262
2 CERTIFICATION f10q0921ex31-1_tffpharma.htm EX-31.1 11247
3 CERTIFICATION f10q0921ex31-2_tffpharma.htm EX-31.2 11435
4 CERTIFICATION f10q0921ex32-1_tffpharma.htm EX-32.1 5262
5 GRAPHIC image_001.jpg GRAPHIC 8363
  Complete submission text file 0001213900-21-059329.txt   2729021

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tffp-20210930.xsd EX-101.SCH 37646
7 XBRL CALCULATION FILE tffp-20210930_cal.xml EX-101.CAL 19970
8 XBRL DEFINITION FILE tffp-20210930_def.xml EX-101.DEF 135345
9 XBRL LABEL FILE tffp-20210930_lab.xml EX-101.LAB 299418
10 XBRL PRESENTATION FILE tffp-20210930_pre.xml EX-101.PRE 147294
11 EXTRACTED XBRL INSTANCE DOCUMENT f10q0921_tffpharma_htm.xml XML 257116
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

EIN.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 211410277
SIC: 2834 Pharmaceutical Preparations